Method of diagnosing overactive bladder disorder

A method of diagnosing overactive bladder disorder (OAB), the method comprising:

• measuring the concentrations of one or more of adenosine triphosphate (ATP), acetylcholine (ACh), nitric oxide (NO) and interleukin 5 (IL-5) in a sample obtained from a subject;
• normalising the concentrations to the concentration of creatinine (Cr) in the sample;
• range standardising the normalised concentrations and age of the subject to the following values:
• Age to 120 years old;
• ATP/Cr to 0.000001;
• ACh/Cr to 0.1;
• NO to 20000;
• IL-5/Cr to 100;
• wherein the likelihood of having OAB (pOAB)=1/(1+e∧(-x)), where X=one or more of the following:
• (−2.688±1.050)+5.472±2.098×subject's age+1.356-0.559×Gender (Female=1, Male=0)+(−7.998±40.273)×[IL-5/Cr];
• (a)
• (−2.141±0.966)+4.506±1.902×subject's age+1.034±0.519×Gender (Female=1, Male-0)+(−5294.063±9075.456)×[ACh/Cr];
• (b)
• (−2.825=1.072)+5.964±2.167×subject's age+1.312±0.562×Gender (Female=1, Male=0)+17.790±58.762×[IL-5/Cr]+(−9180.821±12700.057)×[ACh/Cr];
• (c)
• (−2.993±1.197)+5.580±2.309×subject's age+1.724-0.719×Gender (Female=1, Male-0)+63.571±73.444×[IL-5/Cr]+(−10908.523±13606.752)×[ACh/Cr]+(−566.991±636.589)×[ATP/Cr];
• (d)
• (−3.090±1.200)+5.393±2.256×subject's age+1.797±0.717×Gender (Female=1, Male=0)+34.767±56.331×[IL-5/Cr]+(−562.743±629.316)×[ATP/Cr];
• or (e)
• (−2.650±1.067)+5.516±2.120×subject's age+1.389-0.583×Gender (Female=1, Male=0)+(−4.060±45.238)×[IL-5/Cr]+(−1.456=6.833)×[NO/Cr];
• (f)
• wherein a calculated pOAB value above a first threshold indicates that the subject has a high likelihood of having or developing OAB, and
• wherein the calculated pOAB value below a second threshold indicates that the subject does not have OAB;
• diagnosing the subject with OAB, based on the calculated pOAB value that indicates OAB;
• and
• administering a therapeutic agent to the subject diagnosed as having OAB,
• wherein the therapeutic agent is an antimuscarinic drug or a β3 adrenergic receptor agonist,
• wherein the antimuscarinic drug is selected from one or more of darifenacin, oxybutynin, tolterodine, solifenacin, trospium, flavoxate, propiverine or fesoterodine, and
• wherein the β3 adrenergic receptor agonist is mirabegron.